Table of Contents

1 Study Coverage

• 1.1 ADHD Treatment Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global ADHD Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Stimulant
  • 1.2.3 Non-stimulant
• 1.3 Market by Distribution Channel
  • 1.3.1 Global ADHD Treatment Market Size Growth Rate by Distribution Channel, 2017 VS 2021 VS 2028
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global ADHD Treatment Sales Estimates and Forecasts 2017-2028
• 2.2 Global ADHD Treatment Revenue Estimates and Forecasts 2017-2028
• 2.3 Global ADHD Treatment Revenue by Region: 2017 VS 2021 VS 2028
• 2.4 Global ADHD Treatment Sales by Region
  • 2.4.1 Global ADHD Treatment Sales by Region (2017-2022)
  • 2.4.2 Global Sales ADHD Treatment by Region (2023-2028)
• 2.5 Global ADHD Treatment Revenue by Region
  • 2.5.1 Global ADHD Treatment Revenue by Region (2017-2022)
  • 2.5.2 Global ADHD Treatment Revenue by Region (2023-2028)
• 2.6 North America
• 2.7 Europe
• 2.8 Asia-Pacific
• 2.9 Latin America
• 2.10 Middle East & Africa

3 Competition by Manufacturers

• 3.1 Global ADHD Treatment Sales by Manufacturers
  • 3.1.1 Global Top ADHD Treatment Manufacturers by Sales (2017-2022)
  • 3.1.2 Global ADHD Treatment Sales Market Share by Manufacturers (2017-2022)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of ADHD Treatment in 2021
• 3.2 Global ADHD Treatment Revenue by Manufacturers
  • 3.2.1 Global ADHD Treatment Revenue by Manufacturers (2017-2022)
  • 3.2.2 Global ADHD Treatment Revenue Market Share by Manufacturers (2017-2022)
  • 3.2.3 Global Top 10 and Top 5 Companies by ADHD Treatment Revenue in 2021
• 3.3 Global ADHD Treatment Sales Price by Manufacturers (2017-2022)
• 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global ADHD Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global ADHD Treatment Manufacturers Geographical Distribution
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global ADHD Treatment Sales by Type
  • 4.1.1 Global ADHD Treatment Historical Sales by Type (2017-2022)
  • 4.1.2 Global ADHD Treatment Forecasted Sales by Type (2023-2028)
  • 4.1.3 Global ADHD Treatment Sales Market Share by Type (2017-2028)
• 4.2 Global ADHD Treatment Revenue by Type
  • 4.2.1 Global ADHD Treatment Historical Revenue by Type (2017-2022)
  • 4.2.2 Global ADHD Treatment Forecasted Revenue by Type (2023-2028)
  • 4.2.3 Global ADHD Treatment Revenue Market Share by Type (2017-2028)
• 4.3 Global ADHD Treatment Price by Type
  • 4.3.1 Global ADHD Treatment Price by Type (2017-2022)
  • 4.3.2 Global ADHD Treatment Price Forecast by Type (2023-2028)

5 Market Size by Distribution Channel

• 5.1 Global ADHD Treatment Sales by Distribution Channel
  • 5.1.1 Global ADHD Treatment Historical Sales by Distribution Channel (2017-2022)
  • 5.1.2 Global ADHD Treatment Forecasted Sales by Distribution Channel (2023-2028)
  • 5.1.3 Global ADHD Treatment Sales Market Share by Distribution Channel (2017-2028)
• 5.2 Global ADHD Treatment Revenue by Distribution Channel
  • 5.2.1 Global ADHD Treatment Historical Revenue by Distribution Channel (2017-2022)
  • 5.2.2 Global ADHD Treatment Forecasted Revenue by Distribution Channel (2023-2028)
  • 5.2.3 Global ADHD Treatment Revenue Market Share by Distribution Channel (2017-2028)
• 5.3 Global ADHD Treatment Price by Distribution Channel
  • 5.3.1 Global ADHD Treatment Price by Distribution Channel (2017-2022)
  • 5.3.2 Global ADHD Treatment Price Forecast by Distribution Channel (2023-2028)

6 North America

• 6.1 North America ADHD Treatment Market Size by Type
  • 6.1.1 North America ADHD Treatment Sales by Type (2017-2028)
  • 6.1.2 North America ADHD Treatment Revenue by Type (2017-2028)
• 6.2 North America ADHD Treatment Market Size by Distribution Channel
  • 6.2.1 North America ADHD Treatment Sales by Distribution Channel (2017-2028)
  • 6.2.2 North America ADHD Treatment Revenue by Distribution Channel (2017-2028)
• 6.3 North America ADHD Treatment Market Size by Country
  • 6.3.1 North America ADHD Treatment Sales by Country (2017-2028)
  • 6.3.2 North America ADHD Treatment Revenue by Country (2017-2028)
  • 6.3.3 United States
  • 6.3.4 Canada

7 Europe

• 7.1 Europe ADHD Treatment Market Size by Type
  • 7.1.1 Europe ADHD Treatment Sales by Type (2017-2028)
  • 7.1.2 Europe ADHD Treatment Revenue by Type (2017-2028)
• 7.2 Europe ADHD Treatment Market Size by Distribution Channel
  • 7.2.1 Europe ADHD Treatment Sales by Distribution Channel (2017-2028)
  • 7.2.2 Europe ADHD Treatment Revenue by Distribution Channel (2017-2028)
• 7.3 Europe ADHD Treatment Market Size by Country
  • 7.3.1 Europe ADHD Treatment Sales by Country (2017-2028)
  • 7.3.2 Europe ADHD Treatment Revenue by Country (2017-2028)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia

8 Asia Pacific

• 8.1 Asia Pacific ADHD Treatment Market Size by Type
  • 8.1.1 Asia Pacific ADHD Treatment Sales by Type (2017-2028)
  • 8.1.2 Asia Pacific ADHD Treatment Revenue by Type (2017-2028)
• 8.2 Asia Pacific ADHD Treatment Market Size by Distribution Channel
  • 8.2.1 Asia Pacific ADHD Treatment Sales by Distribution Channel (2017-2028)
  • 8.2.2 Asia Pacific ADHD Treatment Revenue by Distribution Channel (2017-2028)
• 8.3 Asia Pacific ADHD Treatment Market Size by Region
  • 8.3.1 Asia Pacific ADHD Treatment Sales by Region (2017-2028)
  • 8.3.2 Asia Pacific ADHD Treatment Revenue by Region (2017-2028)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 China Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia

9 Latin America

• 9.1 Latin America ADHD Treatment Market Size by Type
  • 9.1.1 Latin America ADHD Treatment Sales by Type (2017-2028)
  • 9.1.2 Latin America ADHD Treatment Revenue by Type (2017-2028)
• 9.2 Latin America ADHD Treatment Market Size by Distribution Channel
  • 9.2.1 Latin America ADHD Treatment Sales by Distribution Channel (2017-2028)
  • 9.2.2 Latin America ADHD Treatment Revenue by Distribution Channel (2017-2028)
• 9.3 Latin America ADHD Treatment Market Size by Country
  • 9.3.1 Latin America ADHD Treatment Sales by Country (2017-2028)
  • 9.3.2 Latin America ADHD Treatment Revenue by Country (2017-2028)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina
  • 9.3.6 Colombia

10 Middle East and Africa

• 10.1 Middle East and Africa ADHD Treatment Market Size by Type
  • 10.1.1 Middle East and Africa ADHD Treatment Sales by Type (2017-2028)
  • 10.1.2 Middle East and Africa ADHD Treatment Revenue by Type (2017-2028)
• 10.2 Middle East and Africa ADHD Treatment Market Size by Distribution Channel
  • 10.2.1 Middle East and Africa ADHD Treatment Sales by Distribution Channel (2017-2028)
  • 10.2.2 Middle East and Africa ADHD Treatment Revenue by Distribution Channel (2017-2028)
• 10.3 Middle East and Africa ADHD Treatment Market Size by Country
  • 10.3.1 Middle East and Africa ADHD Treatment Sales by Country (2017-2028)
  • 10.3.2 Middle East and Africa ADHD Treatment Revenue by Country (2017-2028)
  • 10.3.3 Turkey
  • 10.3.4 Saudi Arabia

11 Company Profiles

• 11.1 Takeda
  • 11.1.1 Takeda Corporation Information
  • 11.1.2 Takeda Overview
  • 11.1.3 Takeda ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.1.4 Takeda ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Takeda Recent Developments
• 11.2 Johnson & Johnson
  • 11.2.1 Johnson & Johnson Corporation Information
  • 11.2.2 Johnson & Johnson Overview
  • 11.2.3 Johnson & Johnson ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.2.4 Johnson & Johnson ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Johnson & Johnson Recent Developments
• 11.3 N ovartis
  • 11.3.1 N ovartis Corporation Information
  • 11.3.2 N ovartis Overview
  • 11.3.3 N ovartis ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.3.4 N ovartis ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 N ovartis Recent Developments
• 11.4 Eli Lilly
  • 11.4.1 Eli Lilly Corporation Information
  • 11.4.2 Eli Lilly Overview
  • 11.4.3 Eli Lilly ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.4.4 Eli Lilly ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Eli Lilly Recent Developments
• 11.5 Tris Pharma
  • 11.5.1 Tris Pharma Corporation Information
  • 11.5.2 Tris Pharma Overview
  • 11.5.3 Tris Pharma ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.5.4 Tris Pharma ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Tris Pharma Recent Developments
• 11.6 Neos Therapeutics
  • 11.6.1 Neos Therapeutics Corporation Information
  • 11.6.2 Neos Therapeutics Overview
  • 11.6.3 Neos Therapeutics ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.6.4 Neos Therapeutics ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 Neos Therapeutics Recent Developments
• 11.7 Mallinckrodt
  • 11.7.1 Mallinckrodt Corporation Information
  • 11.7.2 Mallinckrodt Overview
  • 11.7.3 Mallinckrodt ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.7.4 Mallinckrodt ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Mallinckrodt Recent Developments
• 11.8 Amneal Pharmaceuticals
  • 11.8.1 Amneal Pharmaceuticals Corporation Information
  • 11.8.2 Amneal Pharmaceuticals Overview
  • 11.8.3 Amneal Pharmaceuticals ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.8.4 Amneal Pharmaceuticals ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 Amneal Pharmaceuticals Recent Developments
• 11.9 N oven Pharmaceuticals
  • 11.9.1 N oven Pharmaceuticals Corporation Information
  • 11.9.2 N oven Pharmaceuticals Overview
  • 11.9.3 N oven Pharmaceuticals ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.9.4 N oven Pharmaceuticals ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 N oven Pharmaceuticals Recent Developments
• 11.10 Purdue Parma
  • 11.10.1 Purdue Parma Corporation Information
  • 11.10.2 Purdue Parma Overview
  • 11.10.3 Purdue Parma ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.10.4 Purdue Parma ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Purdue Parma Recent Developments
• 11.11 Jiangsu Chia Tai Fenghai Pharmaceutical
  • 11.11.1 Jiangsu Chia Tai Fenghai Pharmaceutical Corporation Information
  • 11.11.2 Jiangsu Chia Tai Fenghai Pharmaceutical Overview
  • 11.11.3 Jiangsu Chia Tai Fenghai Pharmaceutical ADHD Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
  • 11.11.4 Jiangsu Chia Tai Fenghai Pharmaceutical ADHD Treatment Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.11.5 Jiangsu Chia Tai Fenghai Pharmaceutical Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 ADHD Treatment Industry Chain Analysis
• 12.2 ADHD Treatment Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 ADHD Treatment Production Mode & Process
• 12.4 ADHD Treatment Sales and Marketing
  • 12.4.1 ADHD Treatment Sales Channels
  • 12.4.2 ADHD Treatment Distributors
• 12.5 ADHD Treatment Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

• 13.1 ADHD Treatment Industry Trends
• 13.2 ADHD Treatment Market Drivers
• 13.3 ADHD Treatment Market Challenges
• 13.4 ADHD Treatment Market Restraints

14 Key Findings in The Global ADHD Treatment Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details

Summary:
Market Analysis and Insights: Global ADHD Treatment Market
Attention deficit and hyperactivity disorder (ADHD), commonly known as ADHD, refers to the occurrence of childhood,A group of syndromes characterized by marked difficulty concentrating, short attention span, hyperactivity, or impulsivity compared with children of the same age. To treat ADHD, the US FDA has approved two types of drugs: stimulants and non-stimulants. Stimulants include methylphenidate, amphetamines Amphetamine, non-stimulants including atomoxetine, guanfacine and clonidine.
Due to the COVID-19 pandemic, the global ADHD Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Stimulant accounting for % of the ADHD Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
China ADHD Treatment market size is valued at US$ million in 2021, while the US and Europe ADHD Treatment are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe ADHD Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of ADHD Treatment include Takeda, Johnson & Johnson, N ovartis, Eli Lilly, Tris Pharma, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals and N oven Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Market Segments
The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.
Segment by Type
Stimulant
Non-stimulant
Segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Consequence of Covid-19 Pandemic
The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the ADHD Treatment market back to the pre-covid levels.
Trends & Prospects
In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Outlook
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Takeda
Johnson & Johnson
N ovartis
Eli Lilly
Tris Pharma
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
N oven Pharmaceuticals
Purdue Parma
Jiangsu Chia Tai Fenghai Pharmaceutical
Frequently Asked Questions
Which is the most lucrative product segment in the ADHD Treatment market?
Which are the prominent strategies of the ADHD Treatment market players?
Which factors are increasing the competition in the ADHD Treatment market?
Which are the recommendations provided by the ADHD Treatment industry experts?
Which region will witness rewarding growth during the forecast period?
What factors will curb the ADHD Treatment market growth?
Which product segment will register the fastest growth rate in the ADHD Treatment market?
Which emerging trends will impact the ADHD Treatment market growth?
Which are the high-impact rendering factors in the ADHD Treatment market?
Which companies will maintain their lead on the ADHD Treatment market?